GENOSS Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2004-02-25
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genoss.com
Clinical Trials
12
Active:2
Completed:5
Trial Phases
1 Phases
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (100.0%)Efficacy and Safety of GENOSS SES in Patients with Coronary Artery Disease
Active, not recruiting
- Conditions
- Coronary Arterial Disease (CAD)
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1116
- Registration Number
- NCT06841510
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Safety and Effectiveness of GENOSS DES in Patients With Multivessel Coronary Artery Disease
Recruiting
- Conditions
- Percutaneous Coronary InterventionMultivessel Coronary Artery Disease
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06168305
- Locations
- 🇰🇷
Korea University GURO Hospital, Seoul, Korea, Republic of
Evaluation of Effectiveness and Safety of Abluminal Biodegradable Polymer Sirolimus-eluting Stent
Recruiting
- Conditions
- Coronary Artery DiseasePercutaneous Coronary Intervention
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06086496
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure
Recruiting
- Conditions
- Coronary Artery DiseasePercutaneous Coronary InterventionDual Antiplatelet Therapy
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06075433
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wŏnju, Gangwon state, Korea, Republic of
Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease
Recruiting
- Conditions
- Percutaneous Coronary InterventionDual Antiplatelet Therapy
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06075420
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wonju, Gangwon state, Korea, Republic of
- Prev
- 1
- 2
- 3
- Next
News
No news found